Zhang L, Wang JY, Zhao CY, Shen C, Chen MR, Tian ZY. Prognostic role of the stromal cell derived factor-1 in patients with hepatitis B virus-related acute-on-chronic liver failure. World J Clin Cases 2024; 12(19): 3845-3853 [PMID: 38994298 DOI: 10.12998/wjcc.v12.i19.3845]
Corresponding Author of This Article
Zhi-Ying Tian, MD, Associate Chief Physician, Department of Gastroenterology, Hengshui People's Hospital, No. 180 Renmin East Road, Hengshui 053000, Hebei Province, China. hshy2024@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li Zhang, Mei-Ru Chen, Zhi-Ying Tian, Department of Gastroenterology, Hengshui People's Hospital, Hengshui 053000, Hebei Province, China
Jian-Yu Wang, Department of Neurology, Hengshui People's Hospital, Hengshui 053000, Hebei Province, China
Cai-Yan Zhao, Chuan Shen, Department of Infection, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Author contributions: Tian ZY designed the study; Wang JY, Zhao CY, Shen C, Chen MR performed the data collection and analysed the data; and Zhang L wrote the manuscript; All authors reviewed the manuscript.
Supported byScience and Technology Project of Hengshui, No. 2019014061Z.
Institutional review board statement: This study was reviewed by the Ethics Committee of the Third Affiliated Hospital of Hebei Medical University, 2021-3-021.
Informed consent statement: The study exclusively utilized anonymized patient data, ensuring no invasion of personal privacy. All patient data were collected, recorded, and managed strictly for research purposes within this study, posing no risk to the participants. Consequently, the ethics committee of the Third Affiliated Hospital of Hebei Medical University has granted a waiver for informed consent.
Conflict-of-interest statement: All authors declare that there is no conflict of interest in this study.
Data sharing statement: Please contact the corresponding author for original data.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Ying Tian, MD, Associate Chief Physician, Department of Gastroenterology, Hengshui People's Hospital, No. 180 Renmin East Road, Hengshui 053000, Hebei Province, China. hshy2024@163.com
Received: March 9, 2024 Revised: May 7, 2024 Accepted: May 13, 2024 Published online: July 6, 2024 Processing time: 111 Days and 23.3 Hours
Abstract
BACKGROUND
Stromal cell derived factor-1 (SDF-1) plays a pivotal role in the recruitment of stem cells to injured livers. However, the changes of SDF-l in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) have yet to be elucidated.
AIM
To study the SDF-1 changes in patients with HBV-related ACLF.
METHODS
30 patients with HBV-related ACLF, 27 patients with chronic hepatitis B and 20 healthy individuals are involved in our study. The SDF-l mRNA expression in liver tissue was detected by quantitative real-time polymerase chain reaction. Immunohistochemical staining was performed to illustrate the expression of SDF-l, CXC receptor 4 (CXCR4) and Ki67. The serum SDF-l concentrations were also detected by enzyme-linked immunosorbent assays.
RESULTS
The expression of SDF-1 mRNA from ACLF patients was remarkably higher than that from other patients (both P < 0.05). The expression of SDF-l, CXCR4 and Ki67 from ACLF were the highest among the three groups (all P < 0.01). The serum SDF-l levels in ACLF patients were significantly lower than that in other patients (both P < 0.01). Moreover, in ACLF patients, the serum SDF-1 Levels were positively correlated with serum total bilirubin and international normalized ratio. In addition, the serum SDF-l levels in survival were significantly lower compared with the non-survivals (P < 0.05). The area under the curve for the serum SDF-1 level in predicting 28-d mortality was 0.722 (P < 0.05).
CONCLUSION
This study provides the SDF-1 changes in patients with HBV-related ACLF. The SDF-1 Level at admission may serve as a promising prognostic marker for predicting short-term prognosis.
Core Tip: In this study, we investigated the changes in stromal cell derived factor-1 (SDF-1) in hepatitis B virus (HBV) associated acute-on-chronic liver failure (ACLF) patients. 30 HBV related ACLF patients, 27 chronic hepatitis B patients, and 20 healthy participants participated in our study. Our research findings provide information on the changes in SDF-1 in HBV associated ACLF patients. The level of SDF-1 at admission can serve as a promising prognostic marker for predicting short-term prognosis.
